Artificial intelligence for symptom assessment and patient-reported outcomes in neuro-oncology.

Journal: Journal of neuro-oncology
Published Date:

Abstract

PURPOSE: Patient-reported outcomes (PROs) are critical tools for measuring how patients experience their illness and treatment. Neuropsychiatric symptoms, headaches, seizures, and neurological deficits evolve over time and impact quality of life. In this narrative review, we summarize current literature on PROs in neuro-oncology, extant artificial intelligence (AI) tools for PRO analysis, considerations for real-world application, and ethical implications. METHODS: We searched PubMed/MEDLINE, Embase, and Google Scholar for English-language articles published from January 2015 through April 2026, supplemented by reference-list reviews. Four themes were agreed upon, and authors were assigned to each theme. Authors conducted a literature review, selected articles, and synthesized the information under each of these themes. An initial 78 articles were narrowed down to 53 confirming eligibility if they reported PRO or symptom data in people with brain tumors or computational/AI methods were applied to PRO or symptom monitoring in oncology. Article selection was verified by two senior authors (L.V.Y, A.S.). Older, foundational studies were retained where they remain the primary evidence. RESULTS: The growing volume and complexity of PRO data present challenges for traditional analysis methods. Integrating AI, including machine learning (ML) and large language models (LLMs), may help model longitudinal symptom trajectories to predict deterioration, extract symptoms from free-text clinical notes, and embed outputs in clinical decision support tools. Autonomy, informed consent, data security, bias, access, transparency and accountability should be considered. CONCLUSION: Successful translation will require interpretable, electronic health record-integrated, bias-mitigating tools that allow for actionable insights and preserve patient consent, privacy, and autonomy in this highly vulnerable population. CLINICAL TRIAL NUMBER: Not applicable.

Authors

Keywords

No keywords available for this article.